Sugi Predict

Sugi Predict / Targets / NEK8

NEK8

Serine/threonine-protein kinase Nek8 · Q86SG6 · NEK8 on Sugi Atlas →

0 patent compounds predicted against NEK8, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to NEK8 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... PHASE2COMPLETED
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers PHASE1/PHASE2RECRUITING
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer PHASE2COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b PHASE1COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
The Roles of Neutrophil Elastase in Lung Cancer nanUNKNOWN
Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma nanCOMPLETED
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients nanRECRUITING
Genetics of Neonatal Encephalopathy and Related Disorders nanRECRUITING
LRRK2 Activity and Markers of Parkinson's Disease in G2385R Carriers nanCOMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
Thermogenic Silencer Regulatory Factors in Humans nanACTIVE_NOT_RECRUITING
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study nanCOMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Investigation of Copy Number Variations and Genetic Variants in POI nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a NEK8 binder may also engage these)

ProteinNameSimilarity
D3ZGQ5 — 1.000 D3ZGQ5 →
Q91ZR4 — 1.000 Q91ZR4 →
Q90XC2 — 0.992 Q90XC2 →
Q8VE37 — 0.983 Q8VE37 →
EPHB4 Ephrin type-B receptor 4 0.983 landscape →
O43542 — 0.982 O43542 →
D3ZHP7 — 0.982 D3ZHP7 →
O09127 — 0.982 O09127 →
ULK3 Serine/threonine-protein kinase ULK3 0.981 landscape →
P52785 — 0.981 P52785 →
Q5RCY1 — 0.981 Q5RCY1 →
P55203 — 0.980 P55203 →
Q63285 — 0.980 Q63285 →
Q03145 — 0.980 Q03145 →
Q7ZZC8 — 0.979 Q7ZZC8 →
Q91735 — 0.979 Q91735 →
EPHA2 Ephrin type-A receptor 2 0.979 landscape →
MATK Megakaryocyte-associated tyrosine-protein kinase 0.978 landscape →
P23800 — 0.978 P23800 →
A0A0U1RPR8 — 0.978 A0A0U1RPR8 →
A9S5R3 — 0.977 A9S5R3 →
Q5RCH4 — 0.977 Q5RCH4 →
P51839 — 0.977 P51839 →
Q91048 — 0.977 Q91048 →
Q8BYG9 — 0.976 Q8BYG9 →
Q95266 — 0.976 Q95266 →
P54761 — 0.976 P54761 →
EPHA5 Ephrin type-A receptor 5 0.976 landscape →
O42422 — 0.975 O42422 →
Q8R516 — 0.975 Q8R516 →